IDEXX Q4 & Full Year 2025 Earnings Highlights (NASDAQ: IDXX) | Revenue | | | | Operating | | Diluted | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Profit | | | Earnings Per Share | | | | | Q4 | $1,091M | | | $316M | | $3.08 | | | | | Reported growth: | | +14% | 29% | of Revenue | | | | | | | Organic growth: | | +12% | | | | Reported growth: | | | +18% | | | | | YoY change in basis points: | | | | | | | | CAG Diagnostics Recurring | | | Reported | | +150 | Comparable growth: | ...

Q3 2025 Financial Performance - Revenue reached $1,105 million, with a reported growth of +13% and organic growth of +12%[1] - Operating profit was $355 million[1] - Diluted earnings per share (EPS) stood at $3.40, reflecting a reported growth of +21% and comparable growth of +15%[1] - CAG (Companion Animal Group) revenue was $1,013 million, showing a reported growth of +14% and organic growth of +12%[1] - Water revenue reached $54 million, with a reported growth of +8% and organic growth of +7%[1] - LPD (Livestock, Poultry and Dairy) revenue was $34 million, demonstrating a reported growth of +17% and organic growth of +14%[1] 2025 Outlook - Revenue is projected to be between $4,270 million and $4,300 million, with a reported growth of 9.6% - 10.3% and organic growth of 8.8% - 9.5%[6,7] - Operating margin is expected to be 31.6% - 31.8%, with a reported margin expansion of 260 bps - 280 bps and comparable margin expansion of 80 bps - 100 bps[6,7] - EPS is forecasted to be $12.81 - $13.01, representing a reported growth of 20% - 22% and comparable growth of 12% - 14%[6,7] U.S. Companion Animal Practice Growth - As of September 30, 2025, U S total visits include clinical and non-clinical visits, there were an estimated ~330 million U S total visits in 2024[8,10] - Q3 2025 year-over-year growth in clinical visit was 2.0%[9] - Q3 2025 year-over-year growth in practice revenue was 4.5%[9]